Neurocrine Biosciences Reports Positive Results from P-II study of NBI-1065845 in MDD
Shots:
- Neurocrine reports results from SAVITRI, a P-II study (n=183), evaluating safety and efficacy of NBI-1065845 (AMPA) in adults with MDD who had improper response to other MDD treatment
- Study met both 1EP and 2EP, showing significant reduction in MADRS score at D28 (Dose 1: -4.3; Other dose: -3) and D56 (Dose 1: -7.5; Other dose: -3.6), respectively.
- Common AE observed is headache, no deaths or SAEs; low discontinuation rate. Based on P-II data, company to discuss P-III studies path at FDA meeting
Ref: Neurocrine Biosciences | Image: Neurocrine Biosciences
Related News:- Neurocrine Biosciences Doses First Patient with NBI-1070770 in P-II Trial for Treating Major Depressive Disorder
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
